Fig. 6From: CDKL1 potentiates the antitumor efficacy of radioimmunotherapy by binding to transcription factor YBX1 and blocking PD-L1 expression in lung cancerCDKL1 overexpression inhibits immune evasion in vivo and in vitro, and triple therapy yields the most effective antitumor outcomes in lung cancer. (A) The percentage changes in IFN-γ and GZMB levels in each group were analyzed using flow cytometry in vitro (** P < 0.01, *** P < 0.001). (B) Images of xenograft tumors in C57BL/6J mice. Tumors were measured for volume determination every three days (n = 8, *** P < 0.001). (C) Tumor wet weight was determined (n = 8, ** P < 0.01). (D) The percentage of CD8+ T cells among CD45+ cells, as well as the levels of IFN-γ and GZMB, were assessed in the subcutaneously transplanted tumors on day 14 after inoculation (* P < 0.05, ** P < 0.01, *** P < 0.001). (E) A schematic diagram illustrating the treatment protocol. (F) The mice were randomly divided into nine groups and subjected to treatment. Tumors were measured for volume determination every three days (n = 7). (G) The percentage of CD8+ T cells among CD45+ cells within the subcutaneously transplanted tumors was assessed on day 25 after treatment with various therapies (n = 7). (H) The amount of IFN-γ secreted by CD8+ T cells within the subcutaneously transplanted tumors was determined on day 25 post inoculation (n = 7)Back to article page